parameter estimation module (Simcyp)
Structured Review

Parameter Estimation Module, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/least-squares+optimisation+function/parameter+estimation+module/pmc04244809-230-0-0
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability"
Article Title: Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability
Journal: Frontiers in Pharmacology
doi: 10.3389/fphar.2014.00258
Figure Legend Snippet: Parameters used for the Metoprolol PBPK model (Simcyp V12).
Techniques Used: Molecular Weight, Clinical Proteomics, Binding Assay
Figure Legend Snippet: Parameters used for the zolpidem PBPK model (Simcyp V12).
Techniques Used: Molecular Weight, Clinical Proteomics, Binding Assay, Transduction
Figure Legend Snippet: Parameters used for the Nifedipine PBPK model (Simcyp V12).
Techniques Used: Molecular Weight, Clinical Proteomics, Binding Assay, Formulation, Transduction
Figure Legend Snippet: Parameters used for the triazolam PBPK model (Simcyp V12).
Techniques Used: Molecular Weight, Clinical Proteomics, Binding Assay, Transduction
Figure Legend Snippet: Parameters used for the Quinidine PBPK model (Simcyp V12).
Techniques Used: Molecular Weight, Clinical Proteomics, Binding Assay
Related Articles
Modification:Article Title: Simulation of oral absorption from non-bioequivalent dosage forms of the salt of raltegravir, a poorly soluble acidic drug, using a physiologically based biopharmaceutical modeling (PBBM) approach. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Clinical Proteomics:Article Title: Simulation of oral absorption from non-bioequivalent dosage forms of the salt of raltegravir, a poorly soluble acidic drug, using a physiologically based biopharmaceutical modeling (PBBM) approach. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Concentration Assay:Article Title: Simulation of oral absorption from non-bioequivalent dosage forms of the salt of raltegravir, a poorly soluble acidic drug, using a physiologically based biopharmaceutical modeling (PBBM) approach. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In Vivo:Article Title: Pharmacokinetics of 2-phenoxyethanol and its major metabolite, phenoxyacetic acid, after dermal and inhaled routes of exposure: application to development PBPK model in rats. Article Snippet: 2-Phenoxyethanol (PE), ethylene glycol monophenyl ether, is widely used as a preservative in cosmetic products as well as in non-cosmetics.. Since PE has been used in many types of products, it can be absorbed via dermal or inhaled route for systemic exposures.. In this study, the pharmacokinetic (PK) studies of PE and its major metabolite, phenoxyacetic acid (PAA), after dermal (30 mg and 100 mg) and inhaled administration (77 mg) of PE in rats were performed. |
![Measurement protocol. a Schematic representation. During the warm-up phase, the speed was manually adjusted to achieve the moderate ( <t>\documentclass[12pt]{minimal}</t> \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$v_1$$\end{document} v 1 ) or vigorous ( \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$v_2$$\end{document} v 2 ) HR intensity (](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7158/pmc04687158/pmc04687158__12938_2015_112_Fig1_HTML.jpg)